Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 7889-7897

  Miranda, Les P ^a   Holder, Jerry Ryan ^a   Shi, Licheng ^a   Bennett, Brian ^a   Aral, Jennifer ^a   Gegg, Colin V ^a   Wright, Marie ^a   Walker, Kenneth ^a   Doellgast, George ^a   Rogers, Rick ^a   Li, Hongyan ^a   Valladares, Violeta ^a   Salyers, Kevin ^a   Johnson, Eileen ^a   Wild, Kenneth ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLTRYPTOPHAN[11,18 CITRULLINE 24 HOMOARGININE 25 LYSINE 27,37 BETA(2 NAPHTHYL)ALANINE 31 ASPARTIC ACID 29,24 OCTAHYDROINDOLE 2 CARBOXYLIC ACID 35 PHENYLALANINAMIDE]CALCITONIN GENE RELATED PEPTIDE[8-37]; ACETYLTRYPTOPHAN[24 ARGININE 25 LYSINE 31 ASPARTIC ACID 34 PROLINE 35 PHENYLALANINE]CALCITONIN GENE RELATED PEPTIDE[8-37]; ADRENOMEDULLIN; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN GENE RELATED PEPTIDE[8-37]; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MONKEY; NONHUMAN; RECEPTOR AFFINITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MACACA FASCICULARIS; MALE; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 58149092957     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8009298     Document Type: Article

References (43)

1. Brain, S. D.; Grant, A. D. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. 2004, 84, 903-934.
2. Brain, S. D.; Cox, H. M. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br. J. Pharmacol. 2006, 147, S202-S211.
3. Conner, A. C.; Simms, J.; Barwell, J.; Wheatley, M.; Poyner, D. R. Ligand binding and activation of the CGRP receptor. Biochem. Soc. Trans. 2007, 35, 729-732.
4. Brain, S. D.; Cambridge, H. Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role. Gen. Pharmacol. 1996, 27, 607-611.
5. Doods, H. Development of CGRP antagonists for the treatment of migraine. Curr. Opin. Invest. Drugs (PharmaPress Ltd.) 2001, 2, 1261-1268.
6. Goadsby, P. J. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs 2005, 65, 2557-2567.
7. Fischer, M. J. M.; Koulchitsky, S.; Messlinger, K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J. Neurosci. 2005, 25, 5877-5883.
8. Edvinsson, L.; Petersen, K. A. CGRP-receptor antagonism in migraine treatment. CNS Neurol. Disord.: Drug Targets 2007, 6, 240-246.
9. Paone, D. V.; Shaw, A. W.; Nguyen, D. N.; Burgey, C. S.; Deng, J. Z.; Kane, S. A.; Koblan, K. S.; Salvatore, C. A.; Mosser, S. D.; Johnston, V. K.; Wong, B. K.; Miller-Stein, C. M.; Hershey, J. C.; Graham, S. L.; Vacca, J. P.; Williams, T. M. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2, 2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4, 5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974). J. Med. Chem. 2007, 50, 5564-5567.
10. Troconiz, I. F.; Wolters, J.-M.; Tillmann, C.; Schaefer, H. G.; Roth, W. Modeling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist. Clin. Pharmacokinet. 2006, 45, 715-728.
11. Morris, H. R.; Panico, M.; Etienne, T.; Tippins, J.; Girgis, S. I.; MacIntyre, I. Isolation and characterization of human calcitonin gene-related peptide. Nature 1984, 308, 746-748.
12. Wimalawansa, S. J. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit. Rev. Neurobiol. 1997, 11, 167-239.
13. Hay, D. L.; Conner, A. C.; Poyner, D. R. Calcitonin gene-related peptide and adrenomedullin receptors. Encycl. Biol. Chem. 2004, 1, 212-216.
14. Entzeroth, M.; Doods, H. N.; Wieland, H. A.; Wienen, W. Adrenomedullin mediates vasodilation via CGRP1 receptors. Life Sci. 1995, 56, PL19-PL25.
15. Hay, D. L.; Conner, A. C.; Howitt, S. G.; Smith, D. M.; Poyner, D. R. The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors. J. Mol. Neurosci. 2004, 22, 105-113.
16. Howitt, S. G.; Poyner, D. R. The selectivity and structural determinants of peptide antagonists at the CGRP receptor of rat, L6 myocytes. Br. J. Pharmacol. 1997, 121, 1000-1004.
17. 1H NMR and distance geometry with restrained molecular dynamics. Biochemistry 1991, 30, 575-582.
18. Saha, S.; Waugh, D. J. J.; Zhao, P.; Abel, P. W.; Smith, D. D. Role of conformational constraints of position 7 of the disulfide bridge of h-alpha-CGRP derivatives in their agonist versus antagonist properties. J. Pept. Res. 1998, 52, 112-120.
19. Howitt, S. G.; Kilk, K.; Wang, Y.; Smith, D. M.; Langel, U.; Poyner, D. R. The role of the 8-18 helix of CGRP8-37 in mediating high affinity binding to CGRP receptors; coulombic and steric interactions. Br. J. Pharmacol. 2003, 138, 325-332.
20. Conner, A. C.; Hay, D. L.; Howitt, S. G.; Kilk, K.; Langel, U.; Wheatley, M.; Smith, D. M.; Poyner, D. R. Interaction of calcitonin-gene-related peptide with its receptors. Biochem. Soc. Trans. 2002, 30, 451-455.
21. Chiba, T.; Yamaguchi, A.; Yamatani, T.; Nakamura, A.; Morishita, T.; Inui, T.; Fukase, M.; Noda, T.; Fujita, T. Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am. J. Physiol. 1989, 256, E331-335.
22. Dennis, T.; Fournier, A.; St. Pierre, S.; Quirion, R. Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence for receptor multiplicity. J. Pharmacol. Exp. Ther. 1989, 251, 718-725.
23. Mimeault, M.; Fournier, A.; Dumont, Y.; St-Pierre, S.; Quirion, R. Comparative affinities and antagonistic potencies of various human calcitonin gene-related peptide fragments on calcitonin gene-related peptide receptors in brain and periphery. J. Pharmacol. Exp. Ther. 1991, 258, 1084-1090.
24. Rist, B.; Lacroix, J. S.; Entzeroth, M.; Doods, H. N.; Beck-Sickinger, A. G. CGRP 27-37 analogs with high affinity to the CGRP1 receptor show antagonistic properties in a rat blood flow assay. Regul. Pept. 1999, 79, 153-158.
25. Rist, B.; Entzeroth, M.; Beck-Sickinger, A. G. From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor. J. Med. Chem. 1998, 41, 117-123.
26. Lang, M.; De Pol, S.; Baldauf, C.; Hofmann, H.-J.; Reiser, O.; Beck-Sickinger, A. G. Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J. Med. Chem. 2006, 49, 616-624.
27. Taylor, C. K.; Smith, D. D.; Hulce, M.; Abel, P. W. Pharmacological characterization of novel alpha-calcitonin gene-related peptide (CGRP) receptor peptide antagonists that are selective for human CGRP receptors. J. Pharmacol. Exp. Ther. 2006, 319, 749-757.
28. Struthers, A. D.; Brown, M. J.; Macdonald, D. W.; Beacham, J. L.; Stevenson, J. C.; Morris, H. R.; MacIntyre, I. Human calcitonin gene related peptide: a potent endogenous vasodilator in man. Clin. Sci. 1986, 70, 389-393.
29. Kraenzlin, M. E.; Ch'ng, J. L.; Mulderry, P. K.; Ghatei, M. A.; Bloom, S. R. Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. Regul. Pept. 1985, 10, 189-197.
30. Rink, H. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methyl ester resin. Tetrahedron Lett. 1987, 28, 3787-3790.
31. Atherton, E.; Sheppard, R. C. Solid Phase Peptide Synthesis: A Practical Approach; Oxford University Press: Oxford, U.K., 1989; 203 pp.
32. Wellings, D. A.; Atherton, E. Standard Fmoc protocols. Methods Enzymol. 1997, 289, 44-67.
33. Aletras, A.; Barlos, K.; Gatos, D.; Koutsogianni, S.; Mamos, P. Preparation of the very acid-sensitive Fmoc-Lys(Mtt)-OH. Application in the synthesis of side-chain to side-chain cyclic peptides and oligolysine cores suitable for the solid-phase assembly of MAPs and TASPs. Int. J. Pept. Protein Res. 1995, 45, 488-496.
34. Yue, C.; Thierry, J.; Potier, P. 2-Phenylisopropyl esters as carboxyl terminus protecting groups in the fast synthesis of peptide fragments. Tetrahedron Lett. 1993, 34, 323-326.
35. Coste, J.; Le-Nguyen, D.; Castro, B. PyBOP: a new peptide coupling reagent devoid of toxic byproduct. Tetrahedron Lett. 1990, 31, 205-208.
36. Vine, W.; Beaumont, K.; Gedulin, B.; Pittner, R.; Moore, C. X.; Rink, T. J.; Young, A. A. Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene-related peptide and amylin in rats. Eur. J. Pharmacol. 1996, 314, 115-121.
37. Van Valen, F.; Piechot, G.; Jurgens, H. Calcitonin gene-related peptide (CGRP) receptors are linked to cyclic adenosine monophosphate production in SK-N-MC human neuroblastoma cells. Neurosci. Lett. 1990, 119, 195-198.
38. Davies, D.; Medeiros, M. S.; Keen, J.; Turner, A. J.; Haynes, L. W. Endopeptidase-24.11 cleaves a chemotactic factor from alpha-calcitonin gene-related peptide. Biochem. Pharmacol. 1992, 43, 1753-1756.
39. Mentlein, R.; Roos, T. Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides (Tarrytown, N. Y.) 1996, 17, 709-720.
40. Lundy, F. T.; Salmon, A. L.; Lamey, P.-J.; Shaw, C.; Linden, G. J. Carboxypeptidase-mediated metabolism of calcitonin generelated peptide in human gingival crevicular fluid - a role in periodontal inflammation. J. Clin. Periodontol. 2000, 27, 499-505.
41. Lundy, F. T.; Shaw, C.; McKinnell, J.; Lamey, P. J.; Linden, G. J. Calcitonin gene-related peptide in gingival crevicular fluid in periodontal health and disease. J. Clin. Periodontol. 1999, 26, 212-216.
42. Mulderry, P. K.; Ghatei, M. A.; Bloom, S. P. In vitro production and characterization of low molecular weight forms of calcitonin gene-related peptide immunoreactivity from rat thyroid. Biochem. Biophys. Res. Commun. 1987, 144, 883-890.
43. Boeglin, D.; Hamdan, F. F.; Melendez, R. E.; Cluzeau, J.; Laperriere, A.; Heroux, M.; Bouvier, M.; Lubell, W. D. Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor. J. Med. Chem. 2007, 50, 1401-1408.